RICHARD A SHUBIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- ARCADIA, CA
- NPI
- 1265442180
- Received
- $191,306 in 726 records, 2019 to 2024 ($189,041 general, $2,265 research)
- As principal investigator
- $1,779,924 of research payments to others in 154 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 1 | $15 |
| 2023 | General payment | 1 | $14 |
| 2023 | Research payment | 1 | $200 |
| 2022 | Research payment | 1 | $450 |
| 2021 | General payment | 139 | $36,560 |
| 2021 | Research payment | 1 | $676 |
| 2020 | General payment | 257 | $61,308 |
| 2019 | General payment | 322 | $91,142 |
| 2019 | Research payment | 3 | $938 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 71 | $131,183 |
| Consulting Fee | 15 | $28,573 |
| Food and Beverage | 565 | $12,860 |
| Travel and Lodging | 49 | $8,883 |
| Honoraria | 8 | $7,103 |
| Research payment | 6 | $2,265 |
| Education | 12 | $436 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-09-17 | UCB, Inc. | $15 | Food and Beverage | In-kind items and services | Cimzia Drug, Immunology | 2024 | |
| 2023-07-18 | UCB, Inc. | $14 | Food and Beverage | In-kind items and services | Cimzia Drug, Immunology | 2023 | |
| 2023-01-31 | Eli Lilly and Company | $200 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2022-04-29 | Eli Lilly and Company | $450 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2021-08-19 | Biogen, Inc. | $988 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-07-01 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-06-30 | Biogen, Inc. | $4,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-30 | Biogen, Inc. | $92 | Food and Beverage | Cash or cash equivalent | 2021 | ||
| 2021-06-30 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-06-30 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | ADUHELM Biological, NEUROLOGY | 2021 | |
| 2021-06-25 | Janssen Pharmaceuticals, Inc | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-25 | Alexion Pharmaceuticals, Inc. | $33 | Food and Beverage | In-kind items and services | Soliris Drug, Immunology | 2021 | |
| 2021-06-25 | Janssen Pharmaceuticals, Inc | $4 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-06-24 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-06-24 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | AVONEX Biological, NEUROLOGY | 2021 | |
| 2021-06-24 | Biogen, Inc. | $5 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-06-23 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-06-22 | Almatica Pharma LLC | $26 | Food and Beverage | In-kind items and services | NAPRELAN Drug, ANALGESIC | 2021 | |
| 2021-06-21 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | ADUHELM Biological, NEUROLOGY | 2021 | |
| 2021-06-19 | Biohaven Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-06-18 | Horizon Therapeutics plc | $25 | Food and Beverage | In-kind items and services | UPLIZNA Drug, UPLIZNA | 2021 | |
| 2021-06-18 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-06-16 | Genentech USA, Inc. | $1,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-06-03 | Teva Pharmaceuticals USA, Inc. | $23 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-06-02 | Avanir Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | NUEDEXTA Drug, pseudobulbar affect (PBA) | 2021 | |
| 2021-06-02 | Genentech USA, Inc. | $6 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-05-28 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-26 | Biogen, Inc. | $424 | Consulting Fee | Cash or cash equivalent | AVONEX Biological, NEUROLOGY | 2021 | |
| 2021-05-26 | Biohaven Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-05-25 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-05-24 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-05-21 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | AVONEX Biological, NEUROLOGY | 2021 | |
| 2021-05-21 | Biogen, Inc. | $5 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-05-20 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-05-20 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-19 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-18 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | AIMOVIG Biological, NEUROSCIENCE | 2021 | |
| 2021-05-17 | Teva Pharmaceuticals USA, Inc. | $111 | Education | In-kind items and services | 2021 | ||
| 2021-05-14 | EMD Serono, Inc. | $30 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2021 | |
| 2021-05-13 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-05-12 | ACADIA Pharmaceuticals Inc | $20 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2021 | |
| 2021-05-10 | Amneal Pharmaceuticals LLC | $23 | Food and Beverage | In-kind items and services | RYTARY Drug, NEUROLOGY | 2021 | |
| 2021-05-07 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-05-07 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-06 | Mallinckrodt Hospital Products Inc. | $33 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2021 | |
| 2021-05-06 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-04 | Biogen, Inc. | $8 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-05-02 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-05-01 | Biogen, Inc. | $9 | Education | In-kind items and services | 2021 | ||
| 2021-04-30 | Acorda Therapeutics, Inc | $25 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INBRIJA Drug, PARKINSONS DISEASE | 2021 | |
| 2021-04-29 | MDD US Operations, LLC | $16 | Food and Beverage | Cash or cash equivalent | XADAGO Drug, NEUROLOGY | 2021 | |
| 2021-04-28 | Biogen, Inc. | $3,013 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-04-28 | Teva Pharmaceuticals USA, Inc. | $1,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-04-28 | Adamas Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | GOCOVRI Drug, PD | 2021 | |
| 2021-04-26 | Alexion Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | Soliris Drug, Immunology | 2021 | |
| 2021-04-23 | UCB, Inc. | $32 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2021 | |
| 2021-04-23 | Biohaven Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-04-22 | HARMONY BIOSCIENCES LLC | $1,080 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2021 | |
| 2021-04-21 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-04-20 | Janssen Pharmaceuticals, Inc | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-04-20 | Janssen Pharmaceuticals, Inc | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-04-19 | SK Life Science, Inc. | $21 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-04-19 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-16 | Horizon Therapeutics plc | $49 | Food and Beverage | In-kind items and services | UPLIZNA Drug, UPLIZNA | 2021 | |
| 2021-04-15 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-04-14 | Janssen Pharmaceuticals, Inc | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-04-14 | HARMONY BIOSCIENCES LLC | $10 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2021 | |
| 2021-04-13 | Almatica Pharma LLC | $20 | Food and Beverage | In-kind items and services | NAPRELAN Drug, ANALGESIC | 2021 | |
| 2021-04-13 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-10 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Enspryng Biological, Immunology | 2021 | |
| 2021-04-10 | KYOWA KIRIN, INC. | $22 | Food and Beverage | In-kind items and services | NOURIANZ Drug, ADENOSINE A2A RECEPTORS | 2021 | |
| 2021-04-09 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-07 | SK Life Science, Inc. | $20 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-04-06 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | REYVOW Drug, NEUROSCIENCE;PAIN | 2021 | |
| 2021-04-06 | Biogen, Inc. | $12 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-04-05 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | 2021 | |
| 2021-04-05 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-01 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-04-01 | Amneal Pharmaceuticals LLC | $5 | Food and Beverage | In-kind items and services | RYTARY Drug, NEUROLOGY | 2021 | |
| 2021-03-31 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-30 | Biogen, Inc. | $11 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-25 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-03-25 | Grifols USA, LLC | $11 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2021 | |
| 2021-03-24 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-03-23 | Alnylam Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2021 | |
| 2021-03-23 | Teva Pharmaceuticals USA, Inc. | $4 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-03-19 | Amneal Pharmaceuticals LLC | $800 | Honoraria | Cash or cash equivalent | RYTARY Drug, NEUROLOGY | 2021 | |
| 2021-03-19 | Takeda Pharmaceuticals U.S.A., Inc. | $25 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2021 | |
| 2021-03-19 | Biogen, Inc. | $9 | Education | In-kind items and services | 2021 | ||
| 2021-03-19 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-18 | Biohaven Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-03-17 | Almatica Pharma LLC | $23 | Food and Beverage | In-kind items and services | NAPRELAN Drug, ANALGESIC | 2021 | |
| 2021-03-16 | HARMONY BIOSCIENCES LLC | $360 | Consulting Fee | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2021 | |
| 2021-03-16 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-15 | Avanir Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | NUEDEXTA Drug, pseudobulbar affect (PBA) | 2021 | |
| 2021-03-12 | Novartis Pharmaceuticals Corporation | $45 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-12 | Adamas Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | GOCOVRI Drug, PD | 2021 | |
| 2021-03-12 | Lundbeck LLC | $16 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2021 | |
| 2021-03-12 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-11 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-03-10 | Alexion Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | Soliris Drug, Immunology | 2021 | |
| 2021-03-08 | Janssen Pharmaceuticals, Inc | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-03-08 | Janssen Pharmaceuticals, Inc | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-03-05 | Eli Lilly and Company | $676 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-03-05 | ACADIA Pharmaceuticals Inc | $24 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2021 | |
| 2021-03-05 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-03-05 | Biogen, Inc. | $16 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-04 | Amneal Pharmaceuticals LLC | $800 | Honoraria | Cash or cash equivalent | RYTARY Drug, NEUROLOGY | 2021 | |
| 2021-03-01 | Biogen, Inc. | $2,825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-01 | Biogen, Inc. | $25 | Food and Beverage | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-01 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-26 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-25 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | 2021 | |
| 2021-02-25 | Teva Pharmaceuticals USA, Inc. | $13 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2021 | |
| 2021-02-24 | Teva Pharmaceuticals USA, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-02-24 | AQUESTIVE THERAPEUTICS, INC. | $19 | Food and Beverage | In-kind items and services | SYMPAZAN Drug, Neurology | 2021 | |
| 2021-02-23 | CSL Behring | $15 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2021 | |
| 2021-02-22 | CSL Behring | $16 | Education (2 payments) | In-kind items and services | Hizentra Biological, Immunology | 2021 | |
| 2021-02-19 | Biohaven Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-02-18 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-02-11 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-02-10 | UCB, Inc. | $20 | Food and Beverage | In-kind items and services | Vimpat Drug, Neurology | 2021 | |
| 2021-02-09 | Allergan, Inc. | $27 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2021 | |
| 2021-02-08 | Amneal Pharmaceuticals LLC | $23 | Food and Beverage | In-kind items and services | RYTARY Drug, NEUROLOGY | 2021 | |
| 2021-02-05 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-04 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | ONGENTYS Drug, NEUROLOGY | 2021 | |
| 2021-02-01 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-02-01 | Biogen, Inc. | $6 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-01-29 | Akcea Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | TEGSEDI Drug, NEUROLOGY | 2021 | |
| 2021-01-28 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-01-27 | Janssen Pharmaceuticals, Inc | $5 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-01-27 | Janssen Pharmaceuticals, Inc | $0 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-01-25 | Biohaven Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-01-22 | JAZZ PHARMACEUTICALS INC. | $21 | Food and Beverage | In-kind items and services | SUNOSI Drug, NEUROLOGY | 2021 | |
| 2021-01-21 | Alexion Pharmaceuticals, Inc. | $34 | Food and Beverage | In-kind items and services | Soliris Drug, Immunology | 2021 | |
| 2021-01-21 | HARMONY BIOSCIENCES LLC | $6 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2021 | |
| 2021-01-19 | UCB, Inc. | $18 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2021 | |
| 2021-01-15 | Lundbeck LLC | $24 | Food and Beverage | Cash or cash equivalent | NORTHERA Drug, NEUROLOGY | 2021 | |
| 2021-01-11 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-01-11 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-01-08 | Allergan, Inc. | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-01-08 | Almatica Pharma LLC | $32 | Food and Beverage | In-kind items and services | NAPRELAN Drug, ANALGESIC | 2021 | |
| 2021-01-06 | ACADIA Pharmaceuticals Inc | $18 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2021 | |
| 2021-01-04 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2021 | |
| 2020-12-30 | SK Life Science, Inc. | $16 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-12-24 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-12-23 | Janssen Pharmaceuticals, Inc | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-23 | Biogen, Inc. | $9 | Education | In-kind items and services | 2020 | ||
| 2020-12-21 | UPSHER-SMITH LABORATORIES LLC | $23 | Food and Beverage | In-kind items and services | TOSYMRA SUMATRIPTAN NASAL SPRAY Drug, NEUROLOGY | 2020 | |
| 2020-12-18 | UCB, Inc. | $21 | Food and Beverage | In-kind items and services | Neupro Drug, Neurology | 2020 | |
| 2020-12-17 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-12-16 | Novartis Pharmaceuticals Corporation | $2,025 | Consulting Fee | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-12-16 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-12-16 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-12-14 | Alnylam Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2020 | |
| 2020-12-11 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | LEMTRADA Biological, Neurology | 2020 | |
| 2020-12-10 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-12-07 | Amneal Pharmaceuticals LLC | $25 | Food and Beverage | In-kind items and services | RYTARY Drug, NEUROLOGY | 2020 | |
| 2020-12-07 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-12-05 | Biogen, Inc. | $14 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-12-03 | Biohaven Pharmaceuticals, Inc. | $30 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2020 | |
| 2020-12-03 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-12-02 | Biogen, Inc. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-12-02 | EMD Serono, Inc. | $21 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-12-02 | EMD Serono, Inc. | $21 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-11-25 | Teva Pharmaceuticals USA, Inc. | $1,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-11-23 | SANOFI-AVENTIS U.S. LLC | $19 | Food and Beverage | In-kind items and services | LEMTRADA Biological, Neurology | 2020 | |
| 2020-11-20 | UCB, Inc. | $21 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2020 | |
| 2020-11-18 | Biogen, Inc. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | 2020 | |
| 2020-11-18 | Lundbeck LLC | $24 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2020 | |
| 2020-11-16 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-11-12 | Teva Pharmaceuticals USA, Inc. | $250 | Consulting Fee | Cash or cash equivalent | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-11-12 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-11-12 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-11-11 | Biogen, Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-11-09 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2020 | |
| 2020-11-06 | SANOFI-AVENTIS U.S. LLC | $14 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-11-06 | Biogen, Inc. | $9 | Education | In-kind items and services | 2020 | ||
| 2020-11-05 | Allergan, Inc. | $1,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2020 | |
| 2020-11-04 | Vanda Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2020 | |
| 2020-11-03 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | AIMOVIG Biological, NEUROSCIENCE | 2020 | |
| 2020-11-02 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-10-30 | Allergan, Inc. | $20 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2020 | |
| 2020-10-30 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-10-29 | Biogen, Inc. | $13 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-10-28 | Genentech USA, Inc. | $1,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-10-28 | Grifols USA, LLC | $58 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2020 | |
| 2020-10-26 | ACADIA Pharmaceuticals Inc | $14 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2020 | |
| 2020-10-23 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-10-23 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2020 | |
| 2020-10-22 | Assertio Therapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | CAMBIA Drug, Neurology | 2020 | |
| 2020-10-21 | Lundbeck LLC | $23 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2020 | |
| 2020-10-19 | Alnylam Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2020 | |
| 2020-10-17 | Biogen, Inc. | $9 | Education | In-kind items and services | 2020 | ||
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-10-16 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 |
The latest 200 records of 726.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2023-12-31 | ABBVIE INC. | Sc3 Research Group | $712 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 |
| 2023-12-31 | ABBVIE INC. | Georgetown University Hospital | $1,056 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 |
| 2023-12-31 | ABBVIE INC. | Georgetown University Hospital | $708 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 |
| 2022-12-31 | ABBVIE INC. | SC3 RESEARCH GROUP - PASADENA | $600 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 |
| 2022-12-31 | ABBVIE INC. | Georgetown University Hospital | $981 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 |
| 2022-01-26 | Novartis Pharmaceuticals Corporation | SC3 RESEARCH PASADENA | $5,654 | EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTI | 2022 |
| 2022-01-06 | Celgene Corporation | Sc3 Research Group, Inc | $6,717 | A Multicenter, Longitudinal, Open-Label, Single-Ar - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describin | 2022 |
| 2021-12-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-12-31 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $361 | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure | 2021 |
| 2021-12-31 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $849 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 |
| 2021-11-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-10-29 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-10-21 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $10,150 | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure | 2021 |
| 2021-09-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-08-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-07-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-07-29 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $6,170 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 |
| 2021-06-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-06-21 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $26,916 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 |
| 2021-06-21 | ABBVIE INC. | SC3 RESEARCH GROUP INC | $10,150 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 |
| 2021-05-31 | Eli Lilly and Company | UNIVERSITY CLINICAL TRIALS INC | $50 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 |
| 2021-05-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-05-28 | Eli Lilly and Company | SC3 RESRCH GRP INCRESEDA | $40,881 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 |
| 2021-04-30 | Eli Lilly and Company | RESEARCH AND CARDIOVASCULAR | $50 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 |
| 2021-04-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-04-27 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $4,078 | OCRELIZUMAB IN PATIENTS WITH RMS | 2021 |
| 2021-04-27 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $13,103 | PRIMARY MS | 2021 |
| 2021-04-20 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $2,958 | OCRELIZUMAB IN PATIENTS WITH RMS | 2021 |
| 2021-04-16 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $14,907 | GEN EXTEND | 2021 |
| 2021-04-16 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $7,809 | GENERATION HD1 | 2021 |
| 2021-03-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-03-25 | Eli Lilly and Company | SC3 RESRCH GRP INCRESEDA | $1,303 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 |
| 2021-03-16 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $60,491 | GENERATION HD1 | 2021 |
| 2021-02-26 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-02-23 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $3,000 | PRIMARY MS | 2021 |
| 2021-02-22 | ACADIA Pharmaceuticals Inc | SC3 RESEARCH - PASADENA | $500 | ACP-103-056 | 2021 |
| 2021-02-08 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $8,394 | GENERATION HD1 | 2021 |
| 2021-02-08 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $8,990 | GEN EXTEND | 2021 |
| 2021-01-29 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2021 |
| 2021-01-25 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $8,860 | GEN EXTEND | 2021 |
| 2021-01-20 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $4,431 | GENERATION HD1 | 2021 |
| 2021-01-14 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $2,039 | An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fl | 2021 |
| 2021-01-11 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $10,844 | GEN EXTEND | 2021 |
| 2021-01-11 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $29,856 | GENERATION HD1 | 2021 |
| 2021-01-05 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $3,465 | OCRELIZUMAB IN PATIENTS WITH RMS | 2021 |
| 2020-12-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-12-14 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $5,422 | GEN EXTEND | 2020 |
| 2020-12-03 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $2,039 | AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FL | 2020 |
| 2020-11-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-11-23 | GENZYME CORPORATION | SC3 RESEARCH GROUP INC | $11,000 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2020 |
| 2020-11-20 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $22,155 | GENERATION HD1 | 2020 |
| 2020-11-18 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $4,245 | GEN EXTEND | 2020 |
| 2020-11-18 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $47,595 | GENERATION HD1 | 2020 |
| 2020-11-16 | GENZYME CORPORATION | SC3 RESEARCH GROUP INC | $8,900 | PO- fit-for purpose of the dgital-UPDRS in GBA-PD and iPD | 2020 |
| 2020-11-05 | ACADIA Pharmaceuticals Inc | SC3 RESEARCH GROUP INC DBA SC3 RESEARCH - PASADENA | $1,000 | ACP-103-056 | 2020 |
| 2020-11-02 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $4,368 | GENERATION HD1 | 2020 |
| 2020-10-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-10-27 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $4,174 | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-10-27 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $2,958 | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-10-27 | F. Hoffmann-La Roche AG | SC3 Research Group, Inc. | $4,174 | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-10-26 | GENZYME CORPORATION | SC3 RESEARCH GROUP INC | $2,262 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2020 |
| 2020-10-15 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $3,601 | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-10-07 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $4,745 | GEN EXTEND | 2020 |
| 2020-10-07 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $5,861 | GENERATION HD1 | 2020 |
| 2020-09-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-09-22 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $13,293 | GEN EXTEND | 2020 |
| 2020-09-21 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $26,586 | GENERATION HD1 | 2020 |
| 2020-09-18 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $15,963 | GEN EXTEND | 2020 |
| 2020-09-18 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $64,550 | GENERATION HD1 | 2020 |
| 2020-09-03 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $1,558 | AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FL | 2020 |
| 2020-08-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-08-20 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $7,650 | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-08-18 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $825 | GEN EXTEND | 2020 |
| 2020-08-04 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $599 | GEN EXTEND | 2020 |
| 2020-07-31 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-07-28 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $10,755 | PRIMARY MS | 2020 |
| 2020-07-21 | EMD Serono, Inc. | SC3 RESEARCH GROUP INC | $9,500 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-07-21 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $1,927 | GENERATION HD1 | 2020 |
| 2020-07-21 | EMD Serono, Inc. | SC3 RESEARCH GROUP INC | $1,935 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-07-21 | EMD Serono, Inc. | SC3 RESEARCH GROUP INC | $500 | A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib C | 2020 |
| 2020-07-14 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $8,329 | PRIMARY MS | 2020 |
| 2020-07-09 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $1,092 | GENERATION HD1 | 2020 |
| 2020-07-08 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $6,653 | GEN EXTEND | 2020 |
| 2020-07-07 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $4,197 | GENERATION HD1 | 2020 |
| 2020-07-01 | EMD Serono, Inc. | SC3 Research-Pasadena | $17 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-06-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-06-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | SC3 RESEARCH GROUP INC | $14,000 | A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVAULATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE | 2020 |
| 2020-06-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | SC3 RESEARCH GROUP INC | $6,276 | A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE E | 2020 |
| 2020-06-23 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $8,936 | GEN EXTEND | 2020 |
| 2020-06-18 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $8,358 | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-06-09 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $5,120 | GEN EXTEND | 2020 |
| 2020-06-09 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $3,371 | PRIMARY MS | 2020 |
| 2020-06-04 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $38,251 | GENERATION HD1 | 2020 |
| 2020-05-29 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-05-25 | Celgene Corporation | Sc3 Research Group, Inc | $10,500 | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Mul | 2020 |
| 2020-05-25 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $37,247 | GENERATION HD1 | 2020 |
| 2020-05-07 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $11,096 | GEN EXTEND | 2020 |
| 2020-05-07 | Amneal Pharmaceuticals LLC | SC3 RESEARCH GROUP INC | $5,579 | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-04-30 | EMD Serono, Inc. | SC3 Research-Pasadena | $84 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-04-28 | Genentech, Inc. | SC3 RESEARCH GROUP INC | $1,001 | PRIMARY MS | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Arcadia, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Arcadia, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 55,170 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 56,681 | 10,014,009 | 39,538,223 |
| Median age B01002 | 43.9 | 38.2 | 37.9 |
| Under 18 B01001 | 20.9% | 20.6% | 22.0% |
| 65 and over B01001 | 20.6% | 15.2% | 15.7% |
| Households B11001 | 19,227 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 46.2% | 33.4% | 27.0% |
| Median household income B19013 | $113,516 | $90,112 | $99,122 |
| Median family income B19113 | $130,550 | $101,573 | $113,346 |
| Per capita income B19301 | $57,549 | $45,792 | $49,513 |
| Poverty rate B17001 | 8.6% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.7% | 7.3% | 6.6% |
| Civilian labor force B23025 | 26,225 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 29.3 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 57.4% | 36.0% | 37.1% |
| Housing units B25001 | 20,992 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 58.1% | 45.9% | 55.9% |
| Renters B25003 | 41.9% | 54.1% | 44.1% |
| Median home value B25077 | $1,441,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,191 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 16.7% | 24.7% | 33.8% |
| Black B03002 | 1.6% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 17.5% | 48.4% | 40.2% |
| Asian B03002 | 58.7% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Arcadia, CA.
Comments